Zobrazeno 1 - 10
of 564
pro vyhledávání: '"J Polasek"'
Autor:
Brant A. Inman, Matthew I. Milowsky, Raj S. Pruthi, Marshall Posner, Melissa J. Polasek, Shannon R. Morris, Lori Mixson, Kristin Orr, Elizabeth M. H. Woodson, Andrea T. Kelly, W. Garrett Nichols, Arjun V. Balar
Publikováno v:
Molecular Cancer Therapeutics. 20:P045-P045
Background: PVSRIPO, a novel intratumoral viral immunotherapy, infects cells via CD155, which is widely expressed on solid tumors and antigen-presenting cells (APC). Infection is lethal in malignant cells, but a unique, activating, nonlethal infectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daa5ff2fa850f82192e5d7332b405bdd
https://doi.org/10.1158/1535-7163.targ-21-p045
https://doi.org/10.1158/1535-7163.targ-21-p045
Autor:
Shannon R. Morris, Lori Mixson, Andrea Kelly, Matthew I. Milowsky, Elizabeth M. Woodson, Melissa J. Polasek, Brant A. Inman, Raj S. Pruthi, Garrett Nichols, Arjun Vasant Balar, Kristin Orr
Publikováno v:
Cancer Research. 81:CT242-CT242
Background: The recombinant poliovirus (PV):rhinovirus chimera, PVSRIPO, is a novel non-neurovirulent, intratumoral (IT) immunotherapy showing promising clinical activity in patients (pts) with recurrent glioblastoma and advanced anti-PD-1 refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aa252bf8f07352d4c0f0023c3dd4f59
https://doi.org/10.1158/1538-7445.am2021-ct242
https://doi.org/10.1158/1538-7445.am2021-ct242
Autor:
Brant A. Inman, Raj S. Pruthi, Andrea Kelly, Kristin Orr, Lori Mixson, Elizabeth M. H. Woodson, Matthew I. Milowsky, Shannon R. Morris, Arjun Vasant Balar, Melissa J. Polasek, Marshall R. Posner, Garrett Nichols
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPVSRIPO, a novel intratumoral viral immunotherapy, infects cells via CD155, which is widely expressed on solid tumors and antigen-presenting cells (APC). Infection is lethal in malignant cells, but a unique, activating, nonlethal infection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e67599131359767f65468132ee87c16
https://doi.org/10.1136/jitc-2021-sitc2021.517
https://doi.org/10.1136/jitc-2021-sitc2021.517
Publikováno v:
SLEEP Advances. 2:A44-A44
Background Snoring is the commonest symptom of OSA, occurring in 70%-95% of patients. Snoring noise in severe OSA can reach, and exceed, peaks of 80 decibels(dB). This is a noise level at which permanent hearing loss can occur. Given the chronicity o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1003352131f7e059cbc86c17b9a5fa23
https://doi.org/10.1093/sleepadvances/zpab014.116
https://doi.org/10.1093/sleepadvances/zpab014.116
Autor:
Melissa J. Polasek, Shivanshu Madan, Kasey Hamrick, Vindhya B. Sriramoju, Jonathan D. Cicci, Megan Clarke, Lucius A. Howell, Craig R. Lee, Alexandra Cervantes, Nicholas Varunok, George A. Stouffer, Karen E. Weck, John Andrew Lee
Publikováno v:
Circulation: Genomic and Precision Medicine. 11
Background: CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of using CYP2C19 genotype–guided dual antiplatelet therapy (DAPT) sel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff5ff0c4bf8ba6594ab4385524a855d
https://doi.org/10.1161/circgen.117.002069
https://doi.org/10.1161/circgen.117.002069
Publikováno v:
Expert Review of Clinical Pharmacology. 8:411-421
Dual anti-platelet therapy with aspirin and a P2Y12 inhibitor is the standard of care for patients with acute coronary syndromes (ACS) and for patients undergoing percutaneous coronary intervention (PCI). Clopidogrel is associated with increased risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40190ed07edb01e397db5d4d1d99a331
https://doi.org/10.1586/17512433.2015.1057571
https://doi.org/10.1586/17512433.2015.1057571
Autor:
John Andrew Lee, Craig R. Lee, George A. Stouffer, Karen E. Weck, Lucius A. Howell, Kristen E Tasca, Joseph S. Rossi, Melissa J. Polasek, Jonathan D. Cicci, David C. Plitt, Brent N. Reed
Publikováno v:
Pharmacogenomics. 16:303-313
Aim: An algorithm that uses clinical factors and CYP2C19 genotype to guide P2Y12 inhibitor selection in high-risk patients undergoing percutaneous coronary intervention was implemented at our institution. We sought to evaluate use of this algorithm a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da2dc7038628f9349953d3991f6c68a2
https://doi.org/10.2217/pgs.14.180
https://doi.org/10.2217/pgs.14.180
Autor:
Joel F. Farley, Olivia M. Dong, Mrudula S. Borse, Craig R. Lee, George A. Stouffer, Melissa J. Polasek
Publikováno v:
Pharmacogenomics. 18(12)
Aim: Determine whether using CYP2C19 genotype to optimize antiplatelet therapy selection is cost effective over the initial 30 days and 1-year following percutaneous coronary intervention. Materials & methods: A cost–effectiveness analysis compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb3795e18f15841153b413f5ec2c85c
https://pubmed.ncbi.nlm.nih.gov/28745582
https://pubmed.ncbi.nlm.nih.gov/28745582
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ezer, Péter1,2 (AUTHOR) ezer.peter@pte.hu, Szűcs, Kitti1 (AUTHOR) lukacs.reka@pte.hu, Lukács, Réka1 (AUTHOR) gabor.vilmanyi@pte.hu, Bisztray, Tamás3 (AUTHOR) tamasbi@ifi.uio.no, Vilmányi, Gábor1 (AUTHOR) istvan.szokodi@pte.hu, Szokodi, István1,2 (AUTHOR) komocsi.andras@pte.hu, Komócsi, András1 (AUTHOR) konyi.attila@pte.hu, Kónyi, Attila1,2 (AUTHOR)
Publikováno v:
Journal of Clinical Medicine. Oct2024, Vol. 13 Issue 19, p5742. 17p.